Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis

MOs/MPs collected from skeletal muscle of the CX3CR1^GFP/+ mouse (9, 15) were analyzed according to their GFP and Ly-6C expression during muscle regeneration. Normal muscle contained little CX3CR1^hi/Ly-6C⁻ MOs/MPs (∼200 cells/mg of muscle). Notexin was injected in tibialis anterior (TA) muscles to induce the necrosis/regeneration process. As soon as 90 min after injury, CX3CR1^lo/Ly-6C⁺ MOs/MPs were detected in muscle and rapidly invaded the tissue to reach a maximum point at 24 h after injury (25% of CD45⁺ cells). The CX3CR1^lo/Ly-6C⁺ MO/MP population quickly declined with time, whereas the CX3CR1^hi/Ly-6C⁻ MOs/MPs appeared and continuously increased to reach a plateau at day 7 accounting for 35% of CD45⁺ cells extracted from muscle at this time point (Fig. 1 A).

The MO/MP percentage among CD45⁺ cells is a relative quantification that does not reflect the amount of MOs/MPs actually present in muscle. Thus, we calculated from these data the total number of extracted GFP⁺ cells per milligram of muscle. Results indicated that the extent of the two MO/MP waves was different (Fig. 1 B), and this was confirmed by histological examination (Fig. 1 C). During the first 2 d, as injured myofibers became necrotic, 2,000 to 3,500 GFP⁺ cells/mg of muscle were counted. At 4 and 7 d, when myogenic cells proliferated and further differentiated (Fig. 1 C), five- to sixfold more GFP⁺ MOs/MPs were found in muscle (12,000–16,000 cells/mg; Fig. 1 B). 10 d after injury, when centrally nucleated fibers were visible throughout the injured area (Fig. 1 C), the amount of GFP⁺ cells had dramatically declined to reach <2,000 GFP⁺ cells/mg of tissue (Fig. 1 B).

Between days 1 and 4 after injury, the number of Ly-6C⁻ MOs/MPs increased 20-fold, while the number of Ly-6C⁺ MOs/MPs increased twofold (Fig. 1 B). We analyzed proliferation of both subsets that were isolated from regenerating muscle by cell sorting (Fig. 2 A). Ki67 labeling showed that Ly-6C⁺ MOs/MPs never proliferated, whereas Ly-6C⁻ MOs/MPs partially entered into cell cycle from day 2, and the number of proliferating cells doubled at day 4 and further decreased by twofold at day 7 (Fig. 2 B).

To examine the inflammatory profile of the two MO/MP populations, we analyzed cytokine expression of isolated Ly-6C⁻ and Ly-6C⁺ MOs/MPs at day 4 after injury by RT-PCR. Results showed that Ly-6C⁺ MOs/MPs expressed IL-1β and, to a lesser extent, TNF-α transcripts more strongly than Ly-6C⁻ MOs/MPs (Fig. 2 C). Conversely, Ly-6C⁻ MOs/MPs expressed TGF-β1 and IL-10 more strongly than Ly-6C⁺ MOs/MPs (Fig. 2 C), indicating that Ly-6C⁺ MOs/MPs had an inflammatory profile and Ly-6C⁻ MOs/MPs had an antiinflammatory profile.

We labeled each circulating subset with fluorescent latex beads (LXs) before injury, as previously described (12, 15). Labeling of MOs does not alter their migratory capacities (12). After i.v. LX injection, circulating LX⁺ cells were CX3CR1^hi/Ly-6C⁻ MOs (Fig. 3 A, top, blood); LX⁺ cells were never detected in muscle after injury (Fig. 3 A, top, muscle), indicating that Ly-6C⁻ MOs/MPs appearing in muscle at day 2 were not recruited from blood. After clodronate-encapsulated liposome (clo-lip) injection followed by LX injection, circulating LX⁺ cells were CX3CR1^lo/Ly-6C⁺ MOs, as previously described (15). 36 h after notexin injection, LX⁺ cells were still Ly-6C⁺ MOs (95%) in the blood (Fig. 3 A, bottom, blood), while LX⁺ cells present within muscle were both Ly-6C⁺ and Ly-6C⁻ (38 ± 2 and 61 ± 3%, respectively, based on three experiments; Fig. 3 A, bottom right, muscle). These data indicate that muscle Ly-6C⁻ cells derived from early recruited Ly-6C⁺ MOs/MPs.

Several markers have been associated with MP phenotype transition at the time of resolution of inflammation. Among them, secretory leukocyte protease inhibitor (SLPI) is induced in MPs by proinflammatory signals to trigger down-regulation of proinflammatory cues (29–32). RT-PCR analysis showed that Ly-6C⁺ MOs/MPs strongly expressed SLPI compared with Ly-6C⁻ MOs/MPs (62% increase of band intensity based on three experiments; Fig. 3 B) 4 d after injury. Inversely, peroxisome proliferator-activated receptor (PPAR) γ is expressed by MPs that down-regulate inflammation (33–35). Our results showed that PPAR-γ mRNA was strongly expressed by Ly-6C⁻ compared with Ly-6C⁺ MOs/MPs (49% increase of band intensity based on three experiments; Fig. 3 B).

Forward and side scatter of the two MO/MP subsets isolated at day 7 after injury showed that Ly-6C⁻ MOs/MPs had higher side scatter and were larger than Ly-6C⁺ MOs/MPs (Fig. 3 C), in accordance with a maturation of the Ly-6C⁻ subset. Analysis of differentiation markers showed that Ly-6C⁻ MOs/MPs expressed CD11c and higher levels of F4/80 (Fig. 3 C). Nearly all (> 90%) F4/80⁺ cells were CD11c⁺ and I-A^b+, and no positivity was observed for the dendritic cell marker DEC-205 (unpublished data). These results show that, contrary to Ly-6C⁺ MOs/MPs, Ly-6C⁻ MOs/MPs exhibited high levels of MP differentiation markers.

Collectively, these results suggest that after muscle injury, inflammatory Ly-6C⁺ MOs are recruited from blood, convert to antiinflammatory Ly-6C⁻ MOs/MPs that proliferate in situ, and further differentiate into mature MPs.

To study interactions between MPs and myogenic cells possibly involved in MP phenotype transition, we used in vitro human cell co-cultures. Indeed, in vitro pro- and antiinflammatory MP activation states described in humans most likely correspond to Ly-6C⁺ and Ly-6C⁻ MO/MP profiles found in regenerating mouse muscle. Consistently, LPS/IFN-γ treatment of human MPs induced TNF-α (P < 0.05) and IL-1β (P < 0.05) secretion (Fig. 4 A), whereas dexamethasone (DEX)/IL-10 treatment induced IL-10 (P < 0.05) secretion (Fig. 4 A), as previously shown (36, 37). Because differentiating muscle cells secrete IL-4 (38), a key inducer of alternative activation of MPs (5), we tested IL-4 treatment, which induced TGF-β1 secretion (Fig. 4 A), as previously shown (39).

As a major role of MPs is to operate phagocytosis of dead cells, we evaluated the effect of phagocytosis of muscle cell debris on the MP inflammatory profile. Upon phagocytosis of necrotic mpcs, LPS/IFN-γ–treated MPs both decreased their TNF-α secretion (P < 0.05) and increased their TGF-β1 secretion (P < 0.03; Fig. 4 B). We attempted to inhibit phagocytosis of proinflammatory MPs by colchicine (40), cytochalasin D (41), and recombinant Annexin V (42). Colchicine failed to inhibit phagocytosis, and MPs changed their cytokine secretion upon mpc debris phagocytosis, as in untreated cells (Fig. 4 C). Conversely, phagocytosis was inhibited in the presence of cytochalasin D or recombinant Annexin V; in these conditions, TNF-α and TGF-β1 secretion did not change in the presence of mpc debris (Fig. 4 C). These data indicate that phagocytosis of mpc debris induced a switch of the MP phenotype toward an antiinflammatory profile, as previously shown for other cell types (43–46).

We also evaluated whether interactions with living mpcs may influence MP phenotype. Neither addition of mpcs to previously activated MPs nor addition of mpcs before MP activation substantially altered the MP phenotype (unpublished data). These data show that mpcs neither modified the MP activation state nor prevented acquisition of any given MP phenotype.

In co-culture experiments, we analyzed mpc behavior depending on MP activation state. We have previously shown that untreated MPs stimulate mpc growth and proliferation (26). As shown in Fig. 5, mpc differentiation (Fig. 5 C) and fusion (Fig. 5 D) were also increased by untreated MPs (P ≤ 0.05). LPS/IFN-γ–treated MPs were more potent in enhancing mpc growth (63%; P < 0.05; Fig. 5 A), and accordingly, they enhanced mpc proliferation, as shown by increased BrdU incorporation (25%; P < 0.05; Fig. 5 B). Inversely, both myogenin expression (Fig. 5 C) and myotube formation (Fig. 5 D) were strongly reduced (58 and 68%, respectively; P < 0.05), indicating an inhibition of differentiation by inflammatory MPs. IL-4–treated MPs slightly reduced mpc proliferation (14%; P < 0.05; Fig. 5 B), whereas they stimulated myogenin expression (28%; P < 0.05; Fig. 5 C) and stimulated myotube formation (158%; P < 0.05; Fig. 5 D) compared with untreated MPs. DEX/IL-10–treated MPs did not stimulate growth (Fig. 5 A) and proliferation (Fig. 5 B) compared with untreated MPs but presented a strong prodifferentiating activity, as assessed by increased myogenin expression (52%; P < 0.05; Fig. 5 C) and increased myotube formation (136%; P < 0.01; Fig. 5 D). These results strongly suggest that the activation state of MPs may monitor the myogenic process.

We took advantage of the CD11b–diphtheria toxin receptor (DTR) mouse to study the respective roles of MO/MP subsets during muscle regeneration in vivo, because i.m. injection of clo-lip is toxic for myogenic cells (unpublished data). In CD11b-DTR mice, MOs (and possibly tissue MPs, depending on the way of injection) are depleted after DT injection (47). After a single i.v. DT injection, circulating MO loss occurred from 6 h and reached a maximum at 12 h, which lasted 12 h longer, with subsequent restoration and normalization at 48 h (Fig. 6 A). At maximum depletion, 75–80% of cells in the MO gate had disappeared (Fig. 6 A), as did F4/80⁺, CD11b⁺, and Ly6C⁺ cells (not depicted). The time course of postinjury muscle regeneration in untreated CD11b-DTR mice was similar to that of the C57BL/6 mouse shown in Fig. 1 until day 4, but centrally nucleated myofibers appeared earlier in CD11b-DTR than in C57BL/6 mice (day 7 vs. 10; Fig. 6 B). When DT was simultaneously injected at (Fig. 6 C) or 12 h before (Fig. 6 D) muscle injury, necrotic fibers were removed more slowly, and regeneration was impaired with the appearance of adipose cells (Fig. 6, C and D; and Fig. 7). After double DT injection, both 12 h before and simultaneously at notexin injection (which induced a MO depletion lasting 0–24 h after injury), almost no MO/MP infiltration was observed (Fig. 6 E). None of the hallmarks of regeneration were detected, and persistence of necrotic fibers was observed until day 7 (Fig. 6 E and Fig. 7), although circulating MOs reappeared in the circulation from day 2 after injury (not depicted). When DT was injected 4 d after notexin, no difference was observed compared with the control (Fig. 6 B and Fig. 7), indicating that circulating MOs were no longer recruited into muscle at this time. Notably, i.v.-injected DT did not notably affect i.m. MOs/MPs, as shown by unchanged expression of both F4/80 and CD11b by CD45⁺ cells isolated from muscle (Fig. 6 F, inset).

We attempted to target i.m. antiinflammatory MOs/MPs at a time when phagocytosis of necrotic myofibers is finished (Fig. 6 B and Fig. 7 A). To assess MP depletion in muscle, flow cytometric analysis of CD45⁺ cells was performed 24 h after a single i.m. DT injection. The total number of F4/80⁺ cells present in muscle was diminished by 25% after DT injection (especially F4/80^hi cells, which were diminished by 75%; P < 0.05; Fig. 8 A), indicating that these differentiated FSC^hiF4/80^hi MPs, corresponding to Ly-6C⁻ MPs, were targeted by DT. However, the total number of CD45⁺ cells increased by twofold in DT- versus PBS-injected muscle (Fig. 8 A), indicating that i.m. DT injection induced a secondary inflammation accompanied by the recruitment of F4/80⁻ leukocytes (likely neutrophiles and F4/80^lo/− MOs). Consistently, histological examination of whole TA muscle 4–5 d later showed an area in which new cycles of regeneration were visible, as assessed by the presence of necrotic and basophilic fibers (Fig. 8 B, arrow). This area was restricted to the site of needle puncture and was therefore excluded from the analysis to avoid counting of small regenerating myofibers coming from the secondary lesion (Fig. 8 B). The diameter of centrally nucleated regenerating myofibers was evaluated in the rest of the TA and was found to be reduced by 41% in DT- versus PBS-injected muscle (30.8 vs. 18.2 μm, respectively; P < 0.001; Fig. 8 C).

In the present study, we have shown that (a) injured skeletal muscle selectively recruits Ly-6C⁺ circulating MOs that exhibit an inflammatory profile; (b) within muscle, Ly-6C⁺ MOs switch their phenotype to acquire an antiinflammatory profile, with phagocytosis of muscle cell debris being most likely involved in this transition; (c) as necrosis disappears from the injured area, antiinflammatory Ly-6C⁻ MOs/MPs proliferate and further differentiate into MPs; (d) in vitro, inflammatory MPs enhance myogenic cell proliferation and repress their differentiation, whereas antiinflammatory MPs stimulate myogenesis and fusion; and (e) in vivo depletion of circulating MOs at the time of injury totally prevents muscle regeneration, whereas later depletion of i.m. MPs decreases the diameter of regenerating fibers.

It has been shown that the CX3CR1^lo/Ly-6C⁺ MO population is recruited in injured or inflamed tissues (9, 13, 48). Our experiments using LX-labeled circulating MOs showed that CX3CR1^lo/Ly-6C⁺ MOs were selectively recruited rapidly after muscle injury. Mouse CX3CR1^lo/Ly-6C⁺ MOs and their human analogues bear several chemokine receptors, including CC chemokine receptor (CCR) 2, CCR1, CCR4, CCR7, CXC chemokine receptor 1, and CXC chemokine receptor 2 (9). The corresponding chemokines are expressed by muscle tissue during the first days after injury (the cytokine expression profile is available at http://pepr.cnmcresearch.org) (22, 49, 50). Monocyte chemoattractant protein–1 has been particularly involved in MO recruitment by injured muscle (19, 20). We did not evidence recruitment of CX3CR1^hi/Ly-6C⁻ MOs from blood to muscle. Moreover, transient depletion of circulating MOs during the first 0–24 h after muscle injury showed no subsequent MP infiltration despite reconstitution of the pool of circulating MOs. This suggests that CX3CR1^lo/Ly-6C⁺ MO/MP recruitment takes place early after injury (i.e., within 2–3 d after injury).

Our experiments showed that initially LX-labeled CX3CR1^lo/Ly-6C⁺ MOs converted to CX3CR1^hi/Ly-6C⁻ MOs/MPs from day 2 after injury, indicating a phenotype transition of MOs/MPs within muscle. Consistently, MP differentiation markers were weakly expressed by CX3CR1^lo/Ly- 6C⁺ MOs/MPs and markedly expressed by CX3CR1^hi/ Ly-6C⁻ MOs/MPs (see below). We propose that CX3CR1^lo/Ly-6C⁺ cells, which exhibit an inflammatory phenotype (expressing TNF-α and IL-1β), progressively lose Ly-6C expression while converting to antiinflammatory MOs/MPs (expressing TGF-β1 and IL-10). These data are in accordance with the cytokine mRNA analysis of postinjured muscle extract (available at http://pepr.cnmcresearch.org) (51): TNF-α and IL-1β expression peaks at days 2–3 after injury, whereas IL-10 and TGF-β1 expression increases from day 2 after injury and is maintained throughout regeneration. MP phenotype conversion observed in skeletal muscle further supports previous in vitro evidence that MPs are capable of rapid adaptation to changing environments (4, 6–8) and in vivo demonstration that MPs alter their phenotype according to their tissue environment (52).

MPs participate in both amplification of inflammation at the time of injury and down-regulation of the inflammatory response to avoid excess tissue damage (31, 53, 54). MP stop signals associated with the resolution of inflammation include induction of negative regulators of inflammation in MPs by environmental cues and nonphlogistic phagocytosis. As shown herein, both likely operate during skeletal muscle regeneration. SLPI is considered as a brake on the response of MPs to inflammation (29, 31). Its expression is induced by LPS and IL-6 and leads to inhibition of NO and TNF-α production (30). In vivo, the highest SLPI synthesis occurs during the proinflammatory phase and, thus, anticipates an increase in TGF-β1 and IL-10 production (32). Accordingly, we have shown that CX3CR1^lo/Ly-6C⁺ MOs/MPs expressed more SLPI than CX3CR1^hi/Ly-6C⁻ cells. Another marker associated with the resolution of inflammation by MPs is PPAR-γ. Fatty acids and prostaglandin metabolites bind to PPAR-γ in activated MPs, which triggers inhibition of both inducible NO synthase and release of proinflammatory cytokines (33, 35), thus conferring antiinflammatory properties to PPAR-γ (34). In this paper, we showed that antiinflammatory CX3CR1^hi/Ly-6C⁻ MOs/MPs strongly expressed PPAR-γ. Nonphlogistic phagocytosis by MPs is another signal for switching to healing (31). Binding and phagocytosis of apoptotic cells inhibit secretion of proinflammatory mediators and stimulate secretion of TGF-β1 and IL-10 by inflammatory MPs (43–46). Induction of an antiinflammatory process by phagocytosis of necrotic cells depends on the cell type ingested (42, 43, 55). We showed that both unstimulated and inflammatory MPs adopted an antiinflammatory profile upon phagocytosis of necrotic muscle cell debris and that inhibition of MP phagocytosis prevented this phenotype switch. Collectively, these results strongly suggest that recruited inflammatory CX3CR1^lo/Ly-6C⁺ MOs/ MPs convert to antiinflammatory CX3CR1^hi/Ly-6C⁻ MOs/MPs upon both ingestion of muscle cell debris and expression of stop signals extinguishing inflammation.

Our results showed that once switched, CX3CR1^hi/Ly- 6C⁻ MOs/MPs actively proliferated, therefore contributing to the large amounts of MOs/MPs observed in muscle at days 4–7 after injury. In vitro, MP proliferation is inhibited by inflammatory mediators (LPS, IFN-γ, NO, and IL-6) and is stimulated by TGF-β1 (56–58). Thus, proliferation of recruited MOs/MPs may be caused by changes in their environment, although as yet unknown mechanisms related to the change of phenotype cannot be excluded. Later during muscle regeneration (day 7), CX3CR1^hi/Ly-6C⁻ MO/MP proliferation slowed down simultaneously with the complete differentiation into MPs, as shown by their strong F4/80 expression (59). Almost all F4/80⁺ cells were also positive for CD11c and MHCII, as previously observed after inflammation in various organs (60, 61), and were DEC-205⁻. In the blood, Ly-6C⁻ MOs, which come from Ly-6C⁺ cells, are also CD11c⁺ (12). Therefore, the appearance of CD11c⁺ cells in the muscle may be a recapitulation of conversion from Ly-6C⁺/CD11c⁻ to Ly-6C⁻/CD11c⁺ MOs within the tissue. Thus, proliferating CX3CR1^hi/Ly-6C⁻ MOs/MPs and differentiating CX3CR1^hi/Ly-6C⁻ MPs are associated with the regenerative phase of muscle repair.

Depending on the context, MPs may have supportive or deleterious effects on cells: in chronic diseases, including those affecting skeletal muscle, MPs are deleterious (62, 63), whereas they support tissue repair in muscle and other various tissues, including the liver, brain, peripheral nerve, and epithelium (19–22, 64–67). With the exception of regulation of inflammation, studies documenting a direct role of MPs on cell behavior are scant and include intestinal progenitor proliferation (65), erythroblast proliferation and maturation (68), and oligodendrocytic differentiation and myelination (69). In vitro studies have shown that the MP activation state may direct neural progenitor differentiation toward either neurogenesis or oligodendrogenesis (70). Our results substantiate the view that MP function may be related to an activation state. In co-culture experiments, inflammatory MPs (the counterpart of inflammatory CX3CR1^lo/Ly-6C⁺ cells observed in vivo) stimulated mpc proliferation and inhibited their differentiation. Inversely, IL-4 treated and antiinflammatory MPs exhibited a strong differentiating activity on mpcs, assessed by both stimulation of myogenic program and increase of fusion into multinucleated cells. Molecular mechanisms involved in these processes are currently under investigation. It is likely that cytokines released by activated MPs influence myogenic cell behavior: TNF-α is mitogenic for myoblasts and inhibits their differentiation (71, 72), IL-1β impairs myogenic differentiation through insulin-like growth factor–1 (73), and in vitro effects of TGF-β1 are more controversial, although in vivo neutralization of TGF-β1 in regenerating muscle was shown to reduce the diameter of regenerating myofibers (74). Beyond cytokines, cyclooxygenase 2 and its metabolites may also play a role, as they were shown to be fusogenic and necessary for good muscle repair (75–77).

Previous in vivo studies using different injury models have shown that partial reduction of MO/MP entry into injured muscle hinders muscle regeneration, as shown by a delay in the appearance of regenerating myofibers and the persistence of intermuscular adipocytes (19–22). We observed similar features upon partial inhibition of MO recruitment in toxic-induced muscle regeneration. Moreover, when nearly no MO/MP was allowed to enter damaged muscle, myofibers remained in the necrotic state, indicating the indispensable role of MPs in muscle repair. Interestingly, despite the normalized level of circulating MOs from day 2 after injury, no delayed recruitment was observed, suggesting that signals governing MO recruitment are only transiently expressed by the damaged tissue, as was recently documented in ultraviolet-injured skin (48). Accordingly, depletion of circulating MOs at day 4 after injury had no effect on muscle regeneration. On the other hand, depletion of i.m. antiinflammatory F4/80^hi MOs/MPs at the time of regeneration (i.e., once phagocytosis of necrotic myofibers is achieved) reduced the diameter of the centrally nucleated regenerating myofibers, indicating that these MOs/MPs were involved in fiber growth, in accordance with our in vitro data.

In conclusion, our data demonstrate a phenotype transition operated by recruited MOs/MPs during resolution of inflammation and tissue repair, which is associated with changes in their functions. We propose sequential involvements of these two phenotypically distinct MP populations during skeletal muscle repair as follows: within the first 24–48 h after injury, skeletal muscle recruits inflammatory circulating MOs, which stimulate myogenic cell proliferation and prevent their differentiation. While they are exposed to an inflammatory environment and operate phagocytosis of muscle cell debris, inflammatory MOs/MPs convert to antiinflammatory MOs/MPs. As phagocytosis of necrotic myofibers is finished, these antiinflammatory MOs/MPs actively proliferate and further differentiate into antiinflammatory MPs that sustain myogenic differentiation and myofiber growth in addition to their protective effect on differentiating myotubes (27) and their effect on fiber membrane repair (78).

C57BL/6, CX3CR1^gfp/+ (9), and CD11b-DTR (provided by J.S. Duffield, Harvard Medical School, Boston, MA) (47) mice were bred and used according to French legislation. Experiments were conducted at 4–8 wk of age.

10 μl notexin (25 μg/ml in PBS; Latoxan) was injected in the TA. For histological analysis, muscles were prepared as previously described (27). Quantitative analysis of muscle regeneration was performed on the entire injured area: approximately seven fields (20× objective; PL Flustar; Carl Zeiss MicroImaging, Inc.) were analyzed in each mouse, representing 300–400 fibers per mouse. Myofiber diameter was evaluated after collagen IV immunolabeling (see Immunolabeling) on approximately seven fields (20× objective) in each mouse. The small diameter of only centrally nucleated myofibers was evaluated in late-regenerating muscle (nonhatched area in Fig. 8 B) with Axiovision 4.6 software (Carl Zeiss MicroImaging, Inc.), representing 250–350 fibers per mouse. In PBS-injected mice, the punctured fascicule was omitted from analysis.

Fascia of the TA was removed. Muscles were dissociated in DMEM containing collagenase B 0.2% (Roche Diagnostics GmbH) and trypsine-EDTA 0.2% at 37°C for 45 min twice, filtered, and counted. CD45+ cells were isolated using magnetic sorting (Miltenyi Biotec) and stained with PE- or PC5-conjugated anti-Gr1 antibody (which reacts with Ly-6C and Ly-6G, but only Ly-6C is expressed by MOs; eBioscience). Cells were sorted using a cell sorter (Epics Elite; Beckman Coulter). Populations presenting >90% purity were used. In some experiments, PE-conjugated CD11c, I-A^b (BD Biosciences) and F4/80 (AbD Serotec) antibodies were used. Analysis was performed with a cytometer (FACSCalibur; BD Biosciences).

Labeling of circulating MOs was performed exactly as previously described (15) with plain microspheres (Fluoresbrite Polychromatic Red Microspheres 0.5μm, 2.5% solids; PolySciences, Inc.) and clo-lip, which were prepared as previously described (79). Clodronate was a gift of Roche Diagnostics GmbH.

12 ng/g DT was i.v. injected into CD11b-DTR mice. Blood was retroorbitally harvested at various times after injection, and cells were labeled with anti-CD11b, anti-Gr1, and F4/80 antibody and analyzed by flow cytometry. Because of high interindividual variations (3–12% of PBMCs), the number of circulating MOs in control mice was normalized to 5% of PBMCs for each series (mean calculated with >25 mice). To deplete infiltrated MOs/MPs, 25 ng/g DT in <10 μl was i.m. injected at days 5 and 6 after injury. Controls included injection of PBS.

Muscle slides were incubated with anticollagen IV antibody (1:50; Chemicon International, Inc.) revealed with Cy5-conjugated anti–rabbit antibody. Mouse-sorted cells were centrifugated on slides and labeled with 1 μg/ml anti-Ki67 antibody (Abcam plc), revealed with FITC-conjugated anti–rabbit antibody. Cultured human mpcs were incubated with 60 μg/ml antidesmin antibody (Abcam plc), revealed by a Cy3-conjugated anti–rabbit antibody, and with 10 μg/ml antimyogenin antibody (BD Biosciences), revealed by a biotinylated anti–mouse (Vector Laboratories) and by dichlorotriazinglaminofluorescein-streptavidin (Beckman Coulter). Controls included incubation with whole rabbit or mouse IgGs. Other secondary antibodies and IgGs were obtained from Jackson ImmunoResearch Laboratories.

Total RNA was prepared from sorted cells using the RNeasy mini kit (QIAGEN). 0.5 μg of total RNA was reverse transcripted using Superscript II reverse transcriptase and amplified with a platinum Taq DNA polymerase (Invitrogen) and the following specific primers (sense and antisense, respectively): β2 microglobulin, 5′-CAGTTCCACCCGCCTCAC-3′ and 5′-CACATGTCTCGATCCCAG-3′; TNF-α, 5′-TTCCAGATTCTTCCCTGAGGT-3′ and 5′-TAAGCAAAAGAGGAGGCAACA-3′; IL-1β, 5′-TGACGTTCCCATTAGACAACTG-3′ and 5′-CCGTCTTTCATTACACAGGACA-3′; TGF-β1, 5′-GAGACGGAATACAGGGCTTTC-3′ and 5′-TCTCTGTGGAGCTGAAGCAAT-3′; IL-10, 5′-ACCAGCTGGACAACATACTGC-3′ and 5′-TCACTCTTCACCTGCTCCACT-3′; SLPI, 5′-CCTTAAGCTTGAGAAGCCACA-3′ and 5′-AGCACTTGTATTTGCCGTCAC; and PPAR-γ, 5′-AAGAGCTGACCCAATGGTTG-3′ and 5′-GGATCCGGCAGTTAAGATCA-3′. Amplification was performed at 94°C, 60°C, and 72°C for 1 min for each step for 30 cycles. 10 μl of amplification products was subjected to electrophoresis on a 2% agarose gel containing ethidium bromide for visualization. Quantification was performed by using Image software (Scion).

Culture media components were purchased from Invitrogen. Human mpcs were cultured from muscle samples at the time of corrective surgery, in conformity with French legislation (Code de la Santé Publique, livre II), as previously described (26).

MPs were differentiated from MOs isolated from human blood, as previously described (26). Differentiated MPs were further cultured in either RPMI 1640 medium containing 15% FBS or advanced RPMI 1640 medium containing 0.5% FBS (supplemented with 1% sodium pyruvate, 10 mM Hepes, 50 μM β-mercaptoethanol, 1% nonessential amino acids, 100× 1% vitamins). MPs were treated, or not, for 48 h with either 1 μg/ml LPS (Sigma-Aldrich) and 10 ng/ml IFN-γ (PeproTech), or 10 ng/ml IL-4 (PeproTech) or 80 ng/ml DEX (Sigma-Aldrich) and 10 ng/ml IL-10 (PeproTech).

mpc necrosis was induced by H₂O treatment for 1 h at 37°C. 100% of cells were propidium iodide positive. Necrotic mpcs were seeded on MPs (five dead mpcs for one MP) for 3 h at 37°C. MP cultures were washed three times to remove noningested material and further cultured in serum-free advanced RPMI 1640 supplemented medium over 24 h to make conditioned media. In some experiments, cells were treated, as previously described, with 10 μg/ml colchicine (Sigma-Aldrich) (40), 1 μg/ml cytochalasin D (Sigma-Aldrich) (41), or 40 μg/ml recombinant Annexin V (BD Biosciences) (42). Phagocytosis was quantified in the same conditions after incubation with fluorescent microspheres (as described in Labeling of blood MOs). The number of LX⁺ cells was quantified under an inverted microscope and expressed as the percentage of total cells.

mpcs were plated on previously prepared MP cultures (3:1 MP/mpc ratio) in advanced RPMI 1640 supplemented medium, except in some experiments in which MPs and mpcs were seeded together before MP treatment was applied, as described in Human MP cell culture.

mpc growth was evaluated as previously described (26). mpc proliferation was estimated by BrdU incorporation (Roche Diagnostics GmbH). mpc differentiation was evaluated by counting the number of myogenin⁺ cells among desmin⁺ cells. mpc fusion was estimated by counting the number of nuclei per myotube.

All experiments were performed using at least three different cultures or animals in independent experiments. The Student's t test was used for statistical analyses. P < 0.05 was considered significant.

We wish to thank J.S. Duffield for the gift of CD11b-DTR mice, G.J. Randolph for advice on circulating MO labeling, F.J. Authier and P. Lafuste for helpful discussions, and E. Fernandez and M. Balbo for technical assistance.

This work was supported by Association Française contre les Myopathies, the Institut National de la Santé et de la Recherche Médicale, and the Université Paris 12 Val-de-Marne.

The authors have no conflicting financial interests.